In this study, we evaluated BluePrint standard and dual subtypes as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab in a large cohort of patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.